

times the ULN compared to 34% of patients treated with placebo-maintenance. ALT elevations ≥ 3 times the ULN were observed in 5% of patients who received REMICADE-maintenance compared with 4% of patients who received placebo-maintenance. ALT elevations ≥ 5 times ULN were observed in 2% of patients who received REMICADE-maintenance compared to none in patients treated with placebo-maintenance. In UC clinical trials (median follow up 30 weeks. Specifically, the median duration of follow-up was 30 weeks for placebo and 31 weeks for REMICADE.), 17% of patients receiving REMICADE experienced elevations in ALT at >1 to <3 times the ULN compared to 12% of patients treated with placebo. ALT elevations ≥ 3 times the ULN were observed in 2% of patients who received REMICADE compared with 1% of patients who received placebo. ALT elevations ≥ 5 times ULN were observed in $<1\%$ of patients in both REMICADE and placebo groups. In an AS clinical trial (median follow up 24 weeks for placebo group and 102 weeks for REMICADE group) 51% of patients receiving REMICADE experienced elevations in ALT at >1 to <3 times the ULN compared to 15% of patients treated with placebo. ALT elevations ≥ 3 times the ULN were observed in 10% of patients who received REMICADE compared to none in patients who received placebo. ALT elevations ≥ 5 times ULN were observed in 4% of patients who received REMICADE compared to none in patients treated with placebo. In a PsA clinical trial (median follow up 39 weeks for REMICADE group and 18 weeks in placebo group) 50% of patients receiving REMICADE experienced elevations in ALT at >1 to <3 times the ULN compared to 16% of patients treated with placebo. ALT elevations ≥ 3 times the ULN were observed in 7% of patients who received REMICADE compared to none in patients who received placebo. ALT elevations ≥ 5 times ULN were observed in 2% of patients who received REMICADE compared to none in patients treated with placebo. In PsO clinical trials, (ALT values are obtained in 2 phase 3 psoriasis studies with median follow-up of 50 weeks for REMICADE and 16 weeks for placebo). 49% of patients receiving REMICADE experienced elevations in ALT at >1 to <3 times the ULN compared to 24% of patients treated with placebo. ALT ≥ 3 x ULN were observed in 8% of patients who received REMICADE compared to $<1\%$ who received placebo. ALT elevations ≥ 5 x ULN were observed in 3% of patients who received REMICADE compared to none in patients treated with placebo. **Adverse Reactions in Pediatric Crohn's Disease** There were some differences observed in the adverse reactions observed in the pediatric patients receiving REMICADE compared to those observed in adults with CD. The following adverse events were reported more commonly in 103 randomized pediatric CD patients administered 5 mg/kg REMICADE through 54 weeks than in 385 adult CD patients receiving a similar treatment regimen: anemia (11%), blood in stool (10%), leukopenia (9%), flushing (9%), viral infection (8%), neutropenia (7%), bone fracture (7%), bacterial infection (6%), and respiratory tract allergic reaction (6%). Infections were reported in 56% of randomized pediatric patients in Study Peds Crohn's and in 50% of adult patients in Study Crohn's I. In Study Peds Crohn's, infections were reported more frequently for patients who received every 8 week as opposed to every 12 week infusions (74% and 38%, respectively), while serious infections were reported for 3 patients in the every 8 week and 4 patients in the every 12 week maintenance treatment group. The most commonly reported infections were upper respiratory tract infection and pharyngitis, and the most commonly reported serious infection was abscess. Pneumonia was reported for 3 patients, (2 in the every 8 week and 1 in the every 12 week maintenance treatment groups). Herpes zoster was reported for 2 patients in the every 8 week maintenance treatment group. In Study Peds Crohn's, 18% of randomized patients experienced one or more infusion reactions, with no notable difference between treatment groups. Of the 112 patients in Study Peds Crohn's, there were no serious infusion reactions, and 2 patients had non-serious anaphylactoid reactions. Antibodies to REMICADE developed in 3% of pediatric patients in Study Peds Crohn's. Elevations of ALT up to 3 times the upper limit of normal (ULN) were seen in 18% of pediatric patients in CD clinical trials; 4% had ALT elevations ≥ 3 x ULN, and 1% had elevations ≥ 5 x ULN. (Median follow-up was 53 weeks.) **Adverse Reactions in Psoriasis Studies** During the placebo-controlled portion across the three clinical trials up to Week 16, the proportion of patients who experienced at least 1 SAE (defined as resulting in death, life threatening, requires hospitalization, or persistent or significant disability/incapacity) was 1.7% in the 3 mg/kg REMICADE group, 3.2% in the placebo group, and 3.9% in the 5 mg/kg REMICADE group. Among patients in the 2 Phase 3 studies, 12.4% of patients receiving REMICADE 5 mg/kg every 8 weeks through one year of maintenance treatment experienced at least 1 SAE in Study I. In Study II, 4.1% and 4.7% of patients receiving REMICADE 3 mg/kg and 5 mg/kg every 8 weeks, respectively, through one year of maintenance treatment experienced at least 1 SAE. One death due to bacterial sepsis occurred 25 days after the second infusion of 5 mg/kg REMICADE. Serious infections included sepsis, and abscesses. In Study I, 2.7% of patients receiving REMICADE 5 mg/kg every 8 weeks through 1 year of maintenance treatment experienced at least 1 serious infection. In Study II, 1.0% and 1.3% of patients receiving REMICADE 3 mg/kg and 5 mg/kg, respectively, through 1 year of treatment experienced at least 1 serious infection. The most common serious infections (requiring hospitalization) were abscesses (skin, throat, and peri-rectal) reported by 5 (0.7%) patients in the 5 mg/kg REMICADE group. Two active cases of tuberculosis were reported: 6 weeks and 34 weeks after starting REMICADE. In placebo-controlled portion of the psoriasis studies, 7 of 1123 patients who received REMICADE at any dose were diagnosed with at least one NMSC compared to 0 of 334 patients who received placebo. In the psoriasis studies, 1% (15/1373) of patients experienced serum sickness or a combination of arthralgia and/or myalgia with fever, and/or rash, usually early in the treatment course. Of these patients, 6 required hospitalization due to fever, severe myalgia, arthralgia, swollen joints, and immobility. **Other Adverse Reactions** Safety data are available from 4779 REMICADE-treated adult patients, including 1304 with RA, 1106 with CD, 484 with UC, 202 with AS, 293 with PsA, 1373 with plaque PsO and 17 with other conditions. (For information on other adverse reactions in pediatric patients, see *ADVERSE REACTIONS, Adverse Reactions in Pediatric Crohn's Disease*.) Adverse events reported in $\geq 5\%$ of all patients with RA receiving 4 or more infusions are listed below. The types and frequencies of adverse reactions observed were similar in REMICADE-treated RA, AS, PsA, plaque PsO and CD patients except for abdominal pain, which occurred in 26% of REMICADE-treated patients with CD. In the CD studies, there were insufficient numbers and duration of follow-up for patients who never received REMICADE to provide meaningful comparisons. The percentages of adverse events for placebo-treated patients (n=350; average weeks of follow-up 59) and REMICADE-treated patients (n=1129; average weeks of follow-up 66), respectively, are: *Gastrointestinal:* Nausea: 20, 21; Abdominal pain: 8, 12; Diarrhea: 12, 12; Dyspepsia: 7, 10; *Respiratory:* Upper respiratory tract infection: 25, 32; Sinusitis: 8, 14; Pharyngitis: 8, 12; Coughing: 8, 12; Bronchitis: 9, 10; Rhinitis: 5, 8; *Skin and appendages disorders:* Rash: 5, 10; Pruritus: 2, 7; *Body as a whole—general disorders:* Fatigue: 7, 9; Pain: 7, 8; *Resistance mechanism disorders:* Fever: 4, 7; Moniliasis: 3, 5; *Central and peripheral nervous system disorders:* Headache: 14, 18; *Musculoskeletal system disorders:* Back pain: 5, 8; Arthralgia: 7, 8; *Urinary system disorders:* Urinary tract infection: 6, 8; *Cardiovascular disorders, general:* Hypertension: 5, 7. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not predict the rates observed in broader patient populations in clinical practice. The most common serious adverse events observed in clinical trials were infections (see *ADVERSE REACTIONS, Infections*). Other serious, medically relevant adverse events $\geq 0.2\%$ or clinically significant adverse events by body system were as follows: *Body as a whole:* allergic reaction, diaphragmatic hernia, edema, surgical/procedural sequela; *Blood:* pancytopenia; *Cardiovascular:* circulatory failure, hypotension, syncope; *Gastrointestinal:* constipation, gastrointestinal hemorrhage, ileus, intestinal obstruction, intestinal perforation, intestinal stenosis, pancreatitis, peritonitis, proctalgia; *Central & Peripheral Nervous:* meningitis, neuritis, peripheral neuropathy, dizziness; *Heart Rate and Rhythm:* arrhythmia, bradycardia, cardiac arrest, tachycardia; *Liver and Biliary:* biliary pain, cholecystitis, cholelithiasis, hepatitis; *Metabolic and Nutritional:* dehydration; *Musculoskeletal:* intervertebral disk herniation, tendon disorder; *Myo-, Endo-, Pericardial, and Coronary Valve:* myocardial infarction; *Platelet, Bleeding, and Clotting:* thrombocytopenia; *Neoplasms:* basal cell, breast, lymphoma; *Psychiatric:* confusion, suicide attempt; *Red Blood Cell:* anemia, hemolytic anemia; *Reproductive:* menstrual irregularity; *Resistance Mechanism:* cellulitis, sepsis, serum sickness; *Respiratory:* adult respiratory distress syndrome, lower respiratory tract infection (including pneumonia), pleural effusion, pleurisy, pulmonary edema, respiratory insufficiency; *Skin and Appendages:* increased sweating, ulceration; *Urinary:* renal calculus, renal failure; *Vascular (Extracardiac):* brain infarction, pulmonary embolism, thrombophlebitis; *White Cell and Reticuloendothelial:* leukopenia, lymphadenopathy. **Post-marketing Adverse Events** The following adverse events, some with fatal outcome, have been reported during post-approval use of REMICADE: neutropenia (see *WARNINGS, Hematologic Events*), interstitial lung disease (including pulmonary fibrosis/ interstitial pneumonitis and very rare rapidly progressive disease), idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, pericardial effusion, systemic and cutaneous vasculitis, erythema multiforme, Stevens-Johnson Syndrome, toxic epidermal necrolysis, peripheral demyelinating disorders (such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy), psoriasis (including new onset and pustular, primarily palmar/plantar), transverse myelitis, and neuropathies (additional neurologic events have also been observed, see *WARNINGS, Neurologic Events*) and acute liver failure, jaundice, hepatitis, and cholestasis (see *WARNINGS, Hepatotoxicity*). Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to REMICADE exposure. The following serious adverse events have been reported in the post-marketing experience in children: infections (some fatal) including opportunistic infections and tuberculosis, infusion reactions, and hypersensitivity reactions. Serious adverse events in the post-marketing experience with REMICADE in the pediatric population have also included malignancies, including hepatosplenic T-cell lymphomas (see *Boxed WARNINGS and WARNINGS*), transient hepatic enzyme abnormalities, lupus-like syndromes, and the development of autoantibodies. **OVERDOSAGE:** Single doses up to 20 mg/kg have been administered without any direct toxic effect. In case of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment instituted immediately. **Administration Instructions Regarding Infusion Reactions** Adverse effects during administration of REMICADE have included flu-like symptoms, headache, dyspnea, hypotension, transient fever, chills, gastrointestinal symptoms, and skin rashes. Anaphylaxis might occur at any time during REMICADE infusion. Approximately 20% of REMICADE-treated patients in all clinical trials experienced an infusion reaction compared with 10% of placebo-treated patients (see *ADVERSE REACTIONS, Infusion-related Reactions*). Prior to infusion with REMICADE, premedication may be administered at the physician's discretion. Premedication could include antihistamines (anti-H1 +/- anti-H2), acetaminophen and/or corticosteroids. During infusion, mild to moderate infusion reactions may improve following slowing or suspension of the infusion, and upon resolution of the reaction, reinitiation at a lower infusion rate and/or therapeutic administration of antihistamines, acetaminophen, and/or corticosteroids. For patients that do not tolerate the infusion following these interventions, REMICADE should be discontinued. During or following infusion, patients that have severe infusion-related hypersensitivity reactions should be discontinued from further REMICADE treatment. The management of severe infusion reactions should be dictated by the signs and symptoms of the reaction. Appropriate personnel and medication should be available to treat anaphylaxis if it occurs.

REFERENCES: 1. *Am J Respir Crit Care Med.* 2000;161:S221-S247. 2. See latest Centers for Disease Control guidelines and recommendations for tuberculosis testing in immunocompromised patients. 3. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. *Lancet Infect Dis.* 2003;3:148-155. 4. Belhadj K, Reyes F, Farret JP, et al. Hepatosplenic $\gamma\delta$ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. *Blood.* 2003;102(13):4261-4269.

© 2008 Centocor, Inc.
Malvern, PA 19355, USA
1-800-457-6399

License #1242
Revised August 2008
IN08442

Nurses Health Study: SLE Doubles Heart Disease Risk

BY SALLY KOCH KUBETIN
Publication Editor

SAN FRANCISCO — Systemic lupus erythematosus more than doubles a woman's relative risk for cardiovascular disease beyond the effect of traditional determinants, judging from the Nurses Health Study findings.

Earlier research reports have found a significantly greater than twofold increased risk for cardiovascular disease in women with lupus. However, those studies examined risk in lupus populations receiving care at tertiary care centers. The data from this study came from a study of the general population, according to investigator Dr. A. Elisabeth Hak.

The Nurses Health Study includes 121,700 women who enrolled in the prospective cohort study in 1976, when they were between 30 and 55 years old. They had no cardiovascular disease (CVD) or SLE at enrollment. Over 28 years, 148 developed SLE. Hypertension, diabetes, family history of CVD, and NSAID use were more common in the women with SLE and heart disease than in the SLE-free women with heart disease.

There were 20 cases of CVD (16 cases of heart disease and 4 strokes) among the women with SLE and 8,149 (6,254 cases of

heart disease and 1,895 strokes) among the non-SLE group, said Dr. Hak, reporting on the investigation she conducted while at Brigham and Women's Hospital, Boston. Based on follow-up of 2,082 person-years for the women with SLE and 2,932,407 person-years for the SLE-free women, the incidence of CVD was 961 cases per 100,000 person-years for the SLE group and 271 per 100,000 person-years for the non-SLE group.

The age-adjusted relative risk for CVD was 2.75 in the SLE group, versus the non-SLE group. The multivariate-adjusted relative risk was 2.26 in the SLE women relative to the women without SLE after controlling for medication use, age, hypertension, race, diabetes, and serum lipid levels, reported Dr. Hak, now at Erasmus University Medical Centre, Rotterdam (the Netherlands).

The fact that the study enrolled women aged 30-55 years means that it excluded those with younger-onset SLE, in whom CVD may have been more common and severe, she noted at the annual meeting of the American College of Rheumatology. The findings also may have been affected by the fact that the cohort is overwhelmingly white.

Dr. Hak reported having no financial conflicts of interest. ■

Proinflammatory HDL May Be Atherosclerosis Biomarker

BY SALLY KOCH KUBETIN
Publication Editor

SAN FRANCISCO — Proinflammatory HDL cholesterol has promise as a biomarker for atherosclerosis in women with systemic lupus erythematosus.

Findings from a study of 274 women with systemic lupus erythematosus (SLE) and 154 age-matched controls showed that serum levels of proinflammatory HDL cholesterol were likely to be elevated in women found by B-mode ultrasound to have thickened carotid intima, indicative of plaque. Although this association was noted in both the women with SLE and controls, it was stronger in the women with lupus, said Dr. Maureen A. McMahon, a rheumatologist at the Ronald Reagan UCLA Medical Center, Los Angeles.

In particular, carotid artery plaque was found in 16% of the women with lupus and 15% of the women in the control group. Of the women with lupus who had plaque, 80% had measurable proinflammatory HDL cholesterol, compared with 43% of the women with SLE but no plaque. Proinflammatory HDL was found in 44% of the healthy women with plaque, compared with 10% of healthy plaque-free women.

The mean carotid intimal thickness was 0.57 mm² for the women in the SLE group versus 0.51 mm² for the controls, a statistically significant difference. The mean

levels of proinflammatory HDL were highest in the women in the highest quartile for carotid intimal thickness, defined as being greater than 0.67 mm².

Women with SLE had significantly higher rates of hypertension and diabetes, compared with the controls on univariate analysis. However, age and current cigarette smoking were the only other significant risk factors for plaque in these women, according to multivariate analysis, Dr. McMahon said at the annual meeting of the American College of Rheumatology.

Paraoxonase (PON) activity or apolipoprotein A-I did not predict atherosclerosis. Traditional risk factors for atherosclerosis such as hypertension, LDL cholesterol, and other protective components for HDL cholesterol were found not to be surrogates for proinflammatory HDL.

Women with SLE have long been known to have an unexplained increased risk for atherosclerosis. Until now, the underlying mechanisms have not been explained.

None of the women had taken statins within the 3 months preceding the study.

Levels of proinflammatory HDL cholesterol are "remarkably stable" in women with lupus, Dr. McMahon said. Thus, levels do not increase and decrease depending on disease activity, she added, noting this has not been the case in RA.

Dr. McMahon reported that she has no financial conflicts of interest. ■